Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma

Heitmann, Jonas S.; Walz, Juliane S.; Pfluegler, Martin; Kauer, Joseph; Schlenk, Richard F.; Jung, Gundram; Salih, Helmut R.

dc.contributor.author	Heitmann, Jonas S.
dc.contributor.author	Walz, Juliane S.
dc.contributor.author	Pflügler, Martin Sebastian
dc.contributor.author	Kauer, Joseph
dc.contributor.author	Jung, Gundram
dc.contributor.author	Salih, Helmut R.
dc.date.accessioned	2022-05-27T08:31:09Z
dc.date.available	2022-05-27T08:31:09Z
dc.date.issued	2020-08
dc.identifier.issn	2044-6055
dc.identifier.uri	http://hdl.handle.net/10900/127447
dc.language.iso	en	de_DE
dc.publisher	Bmj Publishing Group	de_DE
dc.relation.uri	http://dx.doi.org/10.1136/bmjopen-2020-039639	de_DE
dc.subject.ddc	610	de_DE
dc.title	Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma	de_DE
dc.type	Article	de_DE
utue.quellen.id	20220224105258_00212
utue.personen.roh	Heitmann, Jonas S.
utue.personen.roh	Walz, Juliane S.
utue.personen.roh	Pfluegler, Martin
utue.personen.roh	Kauer, Joseph
utue.personen.roh	Schlenk, Richard F.
utue.personen.roh	Jung, Gundram
utue.personen.roh	Salih, Helmut R.
dcterms.isPartOf.ZSTitelID	Bmj Open	de_DE
dcterms.isPartOf.ZS-Issue	10	de_DE
dcterms.isPartOf.ZS-Volume	10	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE
utue.fakultaet	07 Mathematisch-Naturwissenschaftliche Fakultät	de_DE